Official Opening Of EDDC, Singapore.

Matrix Axuditorium, Biopolis, Singapore, 26 June 2019.

AUM Biosciences will be a part of the official opening of the Experimental Drug Development Centre (EDDC) at the Matrix Auditorium on the 26th of June, 2019.

EDDC, a national platform for drug discovery and development will allow for better coordination and optimised use of public sector resources, giving industry partners and Singapore greater agility to respond to a shifting drug development landscape.

The Guest-of-Honour for this event will be Mr. Heng Swee Keat, Minister for Finance and Chairman of the National Research Foundation (NRF).

For updates about the event – Stay connected with us on LinkedIn

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit